Is depot medroxyprogesterone acetate (DMPA) contraindicated in a woman who has multiple atherosclerotic cardiovascular disease (ASCVD) risk factors, including hypertension, dyslipidemia, diabetes, and a family history of ASCVD?

DMPA is NOT an Absolute Contraindication for Multiple ASCVD Risk Factors

DMPA (depot medroxyprogesterone acetate) is not contraindicated in women with multiple atherosclerotic cardiovascular disease risk factors such as hypertension, dyslipidemia, diabetes, and family history of ASCVD. However, the evidence suggests caution is warranted, and alternative contraceptive methods should be strongly considered given the potential adverse metabolic effects.

Guideline-Based Safety Profile

The 2020 American College of Rheumatology guidelines explicitly state that DMPA is "safe in most women with RMD" with only two specific exceptions listed: positive antiphospholipid antibodies and patients at high risk for osteoporosis 1. Notably, multiple ASCVD risk factors are not listed as contraindications in these comprehensive contraception guidelines 1.

For women with systemic lupus erythematosus (a condition with inherently elevated cardiovascular risk), DMPA remains an acceptable contraceptive option for both low and moderate-to-high disease activity 1.

Metabolic Concerns and Cardiovascular Risk

While not contraindicated, DMPA does have documented adverse effects on cardiovascular risk markers:

Lipid Profile Changes

• Long-term DMPA use significantly worsens lipid parameters: increases in total cholesterol (180.7 vs 133.0 mg/dL), LDL cholesterol (120.0 vs 94.3 mg/dL), triglycerides (126.3 vs 99.0 mg/dL), and decreases in HDL cholesterol (39.7 vs 44.1 mg/dL) 2
• Castelli indices (markers of cardiovascular risk) are significantly elevated with DMPA use (Castelli I: 4.61 vs 3.02; Castelli II: 3.08 vs 2.13) 2
• These changes suggest DMPA "may predispose females to the risk of cardiovascular disease in the long run" 2

Thrombotic Risk

• DMPA increases thrombotic risk through enhanced thrombin generation in animal models, despite paradoxically reducing atherosclerotic plaque burden 3
• A recent cardiovascular review concluded that "combined hormonal contraceptives and injectable depot medroxyprogesterone acetate should be avoided among women with CCD or previous stroke as both forms of contraceptive therapy increase thrombosis risk" 1

Glucose Metabolism

• DMPA use is associated with significantly higher fasting blood glucose levels (84.6 vs 77.8 mg/dL) compared to non-users 2

Clinical Decision Algorithm

For women with multiple ASCVD risk factors seeking contraception:

1. First-line recommendation: Offer intrauterine devices (copper or progestin-releasing) as preferred options 1

   • IUDs have <1% failure rates and are "safe in all women with RMD" 1
   • No systemic metabolic effects that worsen cardiovascular risk

2. Second-line: Consider progestin-only pills or progestin implants 1

   • Progestin implants have limited data but are "likely safe in all women with RMD" 1

3. DMPA may be used if patient preference strongly favors this method and:

   • Patient understands the potential for adverse lipid changes 2
   • Cardiovascular risk factors are being aggressively managed (statins for dyslipidemia, antihypertensives for hypertension, glucose control for diabetes) 1
   • Patient is not at high risk for osteoporosis 1
   • Patient does not have established ASCVD or prior stroke 1

Critical Caveats

• The distinction between ASCVD risk factors versus established ASCVD is crucial: Women with actual coronary disease or prior stroke should avoid DMPA due to thrombotic risk 1
• Duration matters: The adverse metabolic effects of DMPA appear to worsen with continued long-term use 4, 2
• Monitor cardiovascular risk factors closely if DMPA is chosen, with particular attention to lipid profiles and glucose metabolism 2
• DMPA is explicitly contraindicated in women with positive antiphospholipid antibodies due to thrombotic risk 1